At Express Scripts, both Sanofi and Regeneron's Praluent and Amgen's Repatha scored a spot on the preferred formulary, which gives both PCSK9 products a chance to snare the pharmacy benefits manager's patients.
The media blitz over jacked-up drug prices and concerns over slowing growth in China may have temporarily kicked the breath out of pharma valuations, but some analysts think the concerns will be short-lived and a return to growth is inevitable.
Right now, Novartis' Sandoz has the only biosimilar on the U.S. market. And it's looking to make it two.
A month removed from launching the U.S.'s first biosimilar, Novartis is again setting sights on an Amgen cash cow, lining up for FDA approval with a copy of the blockbuster Enbrel.
Payers unhappy with the cost of new PCSK9 drugs are getting some ammo, as top U.S. physicians are recommending against using the drugs in a large patient pool.
One of the original players in the development of Amgen's cancer therapy talimogene laherparepvec (T-Vec), now up under review at the FDA, has started a new biotech focused on oncolytics drug development. And the U.K. company attracted a $30 million startup round from a transatlantic group of venture players to get started with a splash.
Partners Amgen and Allergan say their knockoff of Roche's blockbuster Avastin proved itself on par with its reference product, putting the pair a step closer to biting into the cancer drug's billions in annual revenue.
Amgen has struck a deal to buy in an experimental midstage LDL treatment in a $1.55 billion deal. Amgen is acquiring Dutch biotech Dezima for $300 million up front and $1.25 billion in milestones, tackling another potential blockbuster franchise that has spurred billions of dollars in often frustrating research programs.
Amgen is teaming up with Xencor through a heavily back-loaded deal worth as much as $1.7 billion, collaborating on 6 early-stage programs in immuno-oncology and inflammation.
Nine months after Patrick Soon-Shiong struck a deal to acquire the global rights to a failed cancer drug at Amgen, the biotech billionaire has come back for a second oncology program. Soon-Shiong's NantPharma has in-licensed Amgen's AMG 337, a mid-stage MET inhibitor in the clinic for gastric cancer.